成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. 誘導(dǎo)疾病模型產(chǎn)品 Immunology/Inflammation Anti-infection
  3. 免疫與炎癥疾病模型 消化系統(tǒng)疾病模型 COX Antibiotic Influenza Virus Bacterial
  4. 胃腸炎癥及潰瘍模型 胃腸道疾病模型
  5. 胃潰瘍模型
  6. Indomethacin

Indomethacin  (Synonyms: 吲哚美辛; Indometacin)

目錄號(hào): HY-14397 純度: 99.91%
COA 產(chǎn)品使用指南

Indomethacin (Indometacin) 是一種有效的口服活性 COX1/2 抑制劑，COX-1 和 COX-2 的IC50 值分別為 18 nM 和 26 nM。Indomethacin 具有抗癌和抗感染活性。Indomethacin 可用于癌癥、炎癥和病毒感染的研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Indomethacin Chemical Structure

Indomethacin Chemical Structure

CAS No. : 53-86-1

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥500
In-stock
100 mg ￥140
In-stock
500 mg ￥350
In-stock
1 g ￥450
In-stock
5 g ￥800
In-stock
10 g   詢價(jià)  
50 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Indomethacin:

MCE 顧客使用本產(chǎn)品發(fā)表的 40 篇科研文獻(xiàn)

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research[1][2][3].

IC50 & Target[1]

Human COX-1

18 nM (IC50, in CHO cells)

Human COX-2

26 nM (IC50, in CHO cells)

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
2008 IC50
12.6 μM
Compound: indometacin
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
[PMID: 21354800]
A549 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
[PMID: 20583750]
A549 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
A549 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
A549 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
A549 IC50
40.6 μM
Compound: indomethacin
Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis
Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis
[PMID: 22992107]
Bel-7402 IC50
> 100 μM
Compound: Indomethacin
Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
Bel7402/5-FU IC50
> 100 μM
Compound: Indomethacin
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
BJ IC50
> 50 μM
Compound: C
Cytotoxicity against human BJ cells after 72 hrs by luminescence assay
Cytotoxicity against human BJ cells after 72 hrs by luminescence assay
[PMID: 20129783]
BV-2 IC50
34.5 μM
Compound: Indomethacin
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay
[PMID: 27120704]
BV-2 IC50
35.7 μM
Compound: indomethacin
Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay
Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay
[PMID: 26348503]
BV-2 IC50
7.1 μM
Compound: Indomethacin
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
[PMID: 24042007]
CHO IC50
0.026 μM
Compound: Indomethacin
In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2
In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2
[PMID: 9873621]
CHO IC50
0.049 μM
Compound: Indomethacin
Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2
Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2
10.1016/S0960-894X(96)00501-X
CHO IC50
25 μM
Compound: 5
Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA
Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA
[PMID: 20503989]
CHO IC50
25 μM
Compound: 2
Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA
Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA
[PMID: 21873070]
COS-7 IC50
> 1000 μM
Compound: Indomethacin
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
CV-1 EC50
50 μM
Compound: Indomethacin
Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay
Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay
[PMID: 16643023]
DU-145 IC50
> 100 μM
Compound: 4; Ind
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
Erythrocyte IC50
0.086 μg/mL
Compound: Indomethacin
Hemolytic activity in human RBC assessed as membrane mortification by absorbance method
Hemolytic activity in human RBC assessed as membrane mortification by absorbance method
[PMID: 29803359]
Erythrocyte IC50
40 μg/mL
Compound: Indomethacin
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
[PMID: 30108882]
Erythrocyte IC50
40.04 μg/mL
Compound: Indomethacin
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
[PMID: 30108827]
HCT-116 IC50
136.8 μM
Compound: INDO
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
HCT-15 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
HEK293 IC50
> 50 μM
Compound: C
Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay
Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay
[PMID: 20129783]
HEK293 IC50
> 500 μM
Compound: indomethacin
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
[PMID: 23241029]
HEK293 IC50
12 μM
Compound: Indometacin
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
[PMID: 22541068]
HEK293 IC50
140 μM
Compound: Indometacin
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
[PMID: 22541068]
HEK293 IC50
41 μM
Compound: Indometacin
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
[PMID: 22541068]
HeLa IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
HeLa IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
HeLa IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
HeLa EC50
0.14 nM
Compound: 1, IMN
Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay
Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay
[PMID: 23432095]
HeLa IC50
50 μM
Compound: Indomethacin
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
[PMID: 20583750]
HepG2 IC50
> 50 μM
Compound: C
Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay
Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay
[PMID: 20129783]
HT-29 IC50
> 100 μM
Compound: 4; Ind
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
HT-29 IC50
1052 μM
Compound: Indomethacin
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 22940705]
HT-29 IC50
312.6 μM
Compound: INDO
Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
J774 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay
Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay
[PMID: 24268542]
J774 IC50
29.6 μM
Compound: Indomethacin
Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
[PMID: 24268542]
J774.A1 IC50
28.42 μM
Compound: Indomethacin
Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent
Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent
[PMID: 23688954]
J774.A1 IC50
28.56 μM
Compound: Indomethacin
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs
[PMID: 25140384]
K562 IC50
190 μM
Compound: Indomethacin
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
L02 IC50
> 100 μM
Compound: Indomethacin
Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
LNCaP IC50
> 300 μM
Compound: Indomethacin
Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 28057407]
LNCaP IC50
238.4 μM
Compound: INDO
Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
Macrophage IC50
22 μM
Compound: indomethacin
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
[PMID: 8988605]
MCF7 IC50
> 100 μM
Compound: 4; Ind
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
MCF7 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 20583750]
MCF7 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
MCF7 IC50
> 50 μM
Compound: 1
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 35468536]
MCF7 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
MCF7 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
MCF7 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
MDA-MB-231 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 20583750]
Neutrophil IC50
271.212 μM
Compound: Indomethacin
Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay
Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay
[PMID: 22437110]
Neutrophil IC50
38.3 μM
Compound: Indomethacin
Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry
Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry
[PMID: 21316977]
PC-3 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
[PMID: 20583750]
PC-3 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
Platelet IC50
0.1 μM
Compound: Indomethacin
Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins
Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins
[PMID: 114655]
Platelet IC50
0.21 μM
Compound: Indomethacin
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method
[PMID: 8988600]
Platelet IC50
1.62 μM
Compound: Indomethacin
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method
[PMID: 23639653]
Platelet IC50
2.8 μM
Compound: Indomethacin
Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins
Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins
[PMID: 114655]
Platelet IC50
3.2 μM
Compound: Indomethacin
Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins
Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins
[PMID: 114655]
Raji IC50
> 50 μM
Compound: C
Cytotoxicity against human Raji cells after 72 hrs by luminescence assay
Cytotoxicity against human Raji cells after 72 hrs by luminescence assay
[PMID: 20129783]
RAW IC50
15.37 μM
Compound: indomethacin
Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA
Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA
[PMID: 21381754]
RAW IC50
23.47 μM
Compound: indomethacin
Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method
Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method
[PMID: 21381754]
RAW IC50
48.89 μM
Compound: indomethacin
Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis
Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis
[PMID: 21381754]
RAW264.7 IC50
> 10 μM
Compound: Ind
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay
[PMID: 32823004]
RAW264.7 IC50
> 100 μM
Compound: indomethacin
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 21381754]
RAW264.7 IC50
> 100 μM
Compound: indomethacin
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 21381754]
RAW264.7 CC50
> 200 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 27575472]
RAW264.7 IC50
> 40 μM
Compound: Ind
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay
[PMID: 32823004]
RAW264.7 IC50
> 40 μM
Compound: Ind
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay
[PMID: 32823004]
RAW264.7 CC50
> 50 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay
[PMID: 31365251]
RAW264.7 IC50
> 50 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells by MTT assay
Cytotoxicity against mouse RAW264.7 cells by MTT assay
[PMID: 30920218]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 25555141]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 25555141]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS
[PMID: 22633833]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS
[PMID: 22633833]
RAW264.7 IC50
0.62 μM
Compound: Ind
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
[PMID: 36888988]
RAW264.7 IC50
1.25 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
[PMID: 24806310]
RAW264.7 IC50
10.7 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay
[PMID: 25881822]
RAW264.7 IC50
10.99 μM
Compound: Indometacin
Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay
Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay
[PMID: 34352712]
RAW264.7 IC50
11.6 μM
Compound: Indomethacin
Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
[PMID: 27276091]
RAW264.7 IC50
12.1 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 23755850]
RAW264.7 IC50
12.5 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
[PMID: 26702644]
RAW264.7 IC50
12.96 μM
Compound: indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay
[PMID: 20879743]
RAW264.7 IC50
12.96 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry
[PMID: 21807513]
RAW264.7 IC50
13.2 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis
[PMID: 27865705]
RAW264.7 IC50
14.1 μM
Compound: indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay
[PMID: 25821895]
RAW264.7 IC50
148 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
[PMID: 23566521]
RAW264.7 IC50
15.8 μM
Compound: Indomethacin
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
[PMID: 24963714]
RAW264.7 IC50
16.5 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay
[PMID: 27575472]
RAW264.7 IC50
16.67 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
[PMID: 26615888]
RAW264.7 IC50
16.67 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
[PMID: 24660966]
RAW264.7 IC50
16.7 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay
[PMID: 33533247]
RAW264.7 IC50
18.7 μM
Compound: Indomethacin
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
[PMID: 24963714]
RAW264.7 IC50
20 μM
Compound: Indo
Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay
Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay
[PMID: 22633833]
RAW264.7 IC50
21.1 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay
[PMID: 29261312]
RAW264.7 IC50
24 μM
Compound: Indomethacin
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay
[PMID: 33160760]
RAW264.7 IC50
26.2 μg/mL
Compound: Indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis
[PMID: 33422907]
RAW264.7 IC50
32.2 μM
Compound: Indomethacin
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay
[PMID: 32247751]
RAW264.7 IC50
32.3 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay
[PMID: 33422907]
RAW264.7 IC50
33.6 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
[PMID: 28960979]
RAW264.7 IC50
33.6 μM
Compound: Indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
[PMID: 30024153]
RAW264.7 IC50
34.28 μM
Compound: Indomethacin
Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay
Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay
[PMID: 35660249]
RAW264.7 IC50
38 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay
[PMID: 31365251]
RAW264.7 IC50
4.5 μM
Compound: Indo
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry
[PMID: 25881822]
RAW264.7 IC50
40.3 μM
Compound: Indo
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method
[PMID: 25555141]
RAW264.7 IC50
40.7 μM
Compound: INDO
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
[PMID: 35175765]
RAW264.7 IC50
41 μM
Compound: Indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs
[PMID: 30920218]
RAW264.7 IC50
42.2 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay
[PMID: 26710212]
RAW264.7 IC50
42.3 μM
Compound: Indometacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay
[PMID: 35512012]
RAW264.7 IC50
42.6 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay
[PMID: 26024020]
RAW264.7 IC50
42.6 μM
Compound: indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 25945867]
RAW264.7 IC50
45.51 μM
Compound: Indo
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method
[PMID: 19931461]
RAW264.7 IC50
45.57 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay
[PMID: 30925056]
RAW264.7 IC50
46.5 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method
[PMID: 28561586]
RAW264.7 IC50
52.8 nM
Compound: Indomethacin
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method
[PMID: 19467877]
RAW264.7 IC50
6.3 μM
Compound: indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs
[PMID: 25621853]
RAW264.7 IC50
62.9 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
[PMID: 31403786]
RAW264.7 IC50
8.8 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay
[PMID: 32520548]
RAW264.7 IC50
8.8 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay
[PMID: 31573805]
RAW264.7 IC50
9.2 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay
[PMID: 25881822]
Sf9 IC50
0.75 μM
Compound: 1, Indomethacin
Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis
Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis
[PMID: 21524587]
SK-LU-1 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
SW480 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
SW480 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
SW480 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
TERT-RPE1 IC50
> 40 μM
Compound: 1
Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 35468536]
THP-1 IC50
> 10 μM
Compound: indomethacin
Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
[PMID: 10737736]
THP-1 IC50
> 10 μM
Compound: indomethacin
Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay
Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay
[PMID: 10737736]
THP-1 IC50
0.0036 μM
Compound: indomethacin
Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
[PMID: 10737736]
U-251 IC50
20.45 μM
Compound: Indomethacin
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
U-937 IC50
0.02 μM
Compound: Indomethacin
Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid
Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid
[PMID: 9873621]
VCaP IC50
136.9 μM
Compound: INDO
Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
Vero C1008 CC50
> 100 μM
Compound: 1; INM
Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay
[PMID: 34534839]
Vero C1008 CC50
> 500 μM
Compound: 1; INM
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay
[PMID: 34534839]
體外研究
(In Vitro)

Indomethacin (Indometacin) (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro[2].
Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC50=2μM)[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
Concentration: 0, 20, 50, 100 and 150μM
Incubation Time: 24 hours
Result: Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.

Cell Viability Assay[2]

Cell Line: 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
Concentration: 0, 30 and 80μM
Incubation Time: 24 hours
Result: Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.
體內(nèi)研究
(In Vivo)

Indomethacin 可用于誘導(dǎo)胃潰瘍模型。口服后，藥物吸收迅速且完全，盡管存在個(gè)體間和個(gè)體內(nèi)差異。通常情況下，血漿峰值濃度 (2-3 μg/mL) 在 1-2 小時(shí)內(nèi)達(dá)到。然而，與食物同服會(huì)降低并延遲峰值濃度的出現(xiàn)，但不影響總吸收量。在治療濃度下，90% 的 Indomethacin 與血漿中的白蛋白結(jié)合[4]。

誘導(dǎo)胃潰瘍[5][6]
致病原理
Indomethacin 可通過多種機(jī)制引起胃潰瘍，包括通過抑制前列腺素（PG）合成、減少局部血流量、局部刺激和抑制組織再生而造成的損傷。
具體造模方法：
大鼠：白化病大鼠 • Sprague-Dawley • 雄性 • adult (處理：2 周)
給藥方式：100 mg/kg • 口服 • 單劑量
Note
(1) 所有動(dòng)物給藥前24 h 禁食。
(2) Indomethacin 溶解于含 5% NaOH 的生理鹽水中。
造模成功指標(biāo)
胃組織宏觀改變：胃粘膜皺襞明顯，糜爛嚴(yán)重，潰瘍、出血灶明顯。
組織病理學(xué)變化：粘膜嚴(yán)重糜爛，向下到達(dá)肌層；可見出血浸潤(rùn)、粘膜下層水腫、血管嚴(yán)重充血。
分子變化：顯示出強(qiáng)烈的Tnf-α表達(dá)。
生化變化：MDA、TOS 水平升高，TAS 水平降低，CAT 和 GPx 活性以及 GSH 水平降低。
相關(guān)產(chǎn)品： Indomethacin sodium hydrate (HY-14397A)
拮抗產(chǎn)品： Carnosic acid (HY-N0644)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats[1]
Dosage: 0.01-10 mg/kg
Administration: Oral administration; for 3 hours
Result: Inhibited the carrageenan-induced rat paw oedema (ED50=2.0?mg/kg) and hyperalgesia (ED50=1.5?mg/kg) in a dose-dependent manner.
Animal Model: Male C57BL/6J mice[2]
Dosage: 10 mg/mL
Administration: Oral administration; daily, for 29 days
Result: Delayed the onset of tumor growth and the initial growth rate of the footpad tumors.
Clinical Trial
分子量

357.79

Formula

C19H16ClNO4
CAS 號(hào)
性狀

固體

顏色

White to off-white

中文名稱

吲哚美辛
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : 100 mg/mL (279.49 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

Ethanol 中的溶解度 : 12.5 mg/mL (34.94 mM; 超聲助溶)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 2.7949 mL 13.9747 mL 27.9494 mL
5 mM 0.5590 mL 2.7949 mL 5.5899 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (5.81 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (5.81 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.91%

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 2.7949 mL 13.9747 mL 27.9494 mL 69.8734 mL
5 mM 0.5590 mL 2.7949 mL 5.5899 mL 13.9747 mL
10 mM 0.2795 mL 1.3975 mL 2.7949 mL 6.9873 mL
15 mM 0.1863 mL 0.9316 mL 1.8633 mL 4.6582 mL
20 mM 0.1397 mL 0.6987 mL 1.3975 mL 3.4937 mL
25 mM 0.1118 mL 0.5590 mL 1.1180 mL 2.7949 mL
30 mM 0.0932 mL 0.4658 mL 0.9316 mL 2.3291 mL
DMSO 40 mM 0.0699 mL 0.3494 mL 0.6987 mL 1.7468 mL
50 mM 0.0559 mL 0.2795 mL 0.5590 mL 1.3975 mL
60 mM 0.0466 mL 0.2329 mL 0.4658 mL 1.1646 mL
80 mM 0.0349 mL 0.1747 mL 0.3494 mL 0.8734 mL
100 mM 0.0279 mL 0.1397 mL 0.2795 mL 0.6987 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Indomethacin
目錄號(hào)：
HY-14397
需求量：